Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...
The Scientific Method03:50

The Scientific Method

Chemistry is an empirical science. Scientists often pose questions to understand the chemistry in everyday life and seek answers to these questions. To achieve this, scientists follow a definitive series of steps that together make up the Scientific Method. This approach involves making observations, asking questions, building a hypothesis, conducting experiments, analyzing results, and forming a conclusion.
Sanger Sequencing01:57

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hypothesis: Accept or Fail to Reject?01:17

Hypothesis: Accept or Fail to Reject?

The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null hypothesis and 'fail to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action--introduction.

Seminars in hematology·2011
Same author

Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity.

Seminars in hematology·2011
Same author

Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.

Seminars in hematology·2011
Same author

Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs.

BJU international·2011
Same author

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

Clinical cancer research : an official journal of the American Association for Cancer Research·2008
Same author

Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.

Molecular cancer therapeutics·2005
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
Same journal

Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions.

Seminars in hematology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Taking the Next Step: a Neural Coaptation Orthotopic Hind Limb Transplant Model to Maximize Functional Recovery in Rat
14:18

Taking the Next Step: a Neural Coaptation Orthotopic Hind Limb Transplant Model to Maximize Functional Recovery in Rat

Published on: August 30, 2020

Conclusion and future directions.

Lorenzo M Leoni1

  • 1Actus Advisory, Lugano, Switzerland. lleoni@actus-advisory.com

Seminars in Hematology
|May 3, 2011
PubMed
Summary
This summary is machine-generated.

Bendamustine, an alkylating agent, shows promise in treating lymphoid malignancies. Further research is exploring its unique mechanism of action to optimize its clinical use for better patient outcomes.

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Related Experiment Videos

Last Updated: Jun 2, 2026

Taking the Next Step: a Neural Coaptation Orthotopic Hind Limb Transplant Model to Maximize Functional Recovery in Rat
14:18

Taking the Next Step: a Neural Coaptation Orthotopic Hind Limb Transplant Model to Maximize Functional Recovery in Rat

Published on: August 30, 2020

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Bendamustine is a nitrogen mustard derivative with a benzimidazole ring.
  • Its unique structure suggests potential nucleoside-like properties and prolonged DNA damage.
  • While effective in various B-cell lymphomas, its precise mechanism of action requires elucidation.

Purpose of the Study:

  • To review emerging data on bendamustine's mechanism of action.
  • To provide clinical updates and scientific rationale for its use in lymphoid malignancies.
  • To guide clinicians in the optimal utilization of bendamustine.

Main Methods:

  • Review of preclinical and clinical studies.
  • Analysis of recent clinical trial data.
  • Synthesis of scientific literature on bendamustine's pharmacology.

Main Results:

  • Bendamustine demonstrates significant response rates in follicular lymphoma, chronic lymphocytic leukemia, diffuse B-cell lymphoma, and mantle cell lymphoma.
  • Emerging data suggest unique properties contributing to its efficacy.
  • Clinical trials continue to report impressive results in lymphoid malignancies.

Conclusions:

  • Bendamustine is an effective agent for lymphoid malignancies.
  • Understanding its exact mechanism of action is crucial for optimizing treatment strategies.
  • Further research will enhance the clinical application of bendamustine.